Sunitinib prevents cachexia and prolongs survival of mice bearing renal cancer by restraining STAT3 and MuRF-1 activation in muscle

Oncotarget

Volumn 6, Issue 5, 2015, Pages 3043-3054

  Pretto, Francesca ^a,c   Ghilardi, Carmen ^a   Moschetta, Michele ^a   Bassi, Andrea ^b   Rovida, Alessandra ^a   Scarlato, Valentina ^a   Talamini, Laura ^a   Fiordaliso, Fabio ^a   Bisighini, Cinzia ^a   Damia, Giovanna ^a   Bani, Maria Rosa ^a   Piccirillo, Rosanna ^a   Giavazzi, Raffaella ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b POLITECNICO DI MILANO   (Italy)

^c PHILOCHEM AG   (Switzerland)

Author keywords

Cancer cachexia; Muscle wasting; Renal carcinoma; STAT3; Sunitinib; Xenograft model

Indexed keywords

MUSCLE RING FINGER 1 PROTEIN; STAT3 PROTEIN; SUNITINIB; ANGIOGENESIS INHIBITOR; INDOLE DERIVATIVE; MUSCLE PROTEIN; PROTEIN KINASE INHIBITOR; PYRROLE DERIVATIVE; STAT3 PROTEIN, MOUSE; TRIM63 PROTEIN, MOUSE; UBIQUITIN PROTEIN LIGASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CACHEXIA; CANCER INHIBITION; CONTROLLED STUDY; DRUG DOSE COMPARISON; FEMALE; GASTROCNEMIUS MUSCLE; HEART MUSCLE; HEART WEIGHT; KIDNEY CANCER; MOUSE; MUSCLE ATROPHY; MUSCLE MASS; NONHUMAN; OVERALL SURVIVAL; SURVIVAL TIME; TIBIALIS ANTERIOR MUSCLE; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CARCINOMA, RENAL CELL; DRUG EFFECTS; DRUG SCREENING; HUMAN; KIDNEY NEOPLASMS; MALE; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; NUDE MOUSE; PATHOLOGY; RADIOGRAPHY; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; TIME; TUMOR CELL LINE; TUMOR VOLUME; ULTRASTRUCTURE;

ANGIOGENESIS INHIBITORS; ANIMALS; CACHEXIA; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MALE; MICE, INBRED C57BL; MICE, NUDE; MUSCLE PROTEINS; MUSCLE, SKELETAL; PROTEIN KINASE INHIBITORS; PYRROLES; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TIME FACTORS; TUMOR BURDEN; UBIQUITIN-PROTEIN LIGASES; WEIGHT LOSS; X-RAY MICROTOMOGRAPHY; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84923289520     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2812     Document Type: Article

References (40)

1. Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, Jatoi A, Loprinzi C, MacDonald N, Mantovani G, Davis M, Muscaritoli M, Ottery F, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 2011; 12(5):489-495.
2. Fearon KC, Glass DJ and Guttridge DC. Cancer cachexia: mediators, signaling, and metabolic pathways. Cell Metab. 2012; 16(2):153-166.
3. Piccirillo R, Demontis F, Perrimon N and Goldberg AL. Mechanisms of muscle growth and atrophy in mammals and Drosophila. Dev Dyn. 2014; 243(2):201-215.
4. Egerman MA and Glass DJ. Signaling pathways controlling skeletal muscle mass. Crit Rev Biochem Mol Biol. 2014; 49(1):59-68.
5. Fearon K, Arends J and Baracos V. Understanding the mechanisms and treatment options in cancer cachexia. Nat Rev Clin Oncol. 2013; 10(2):90-99.
6. Mantovani G, Madeddu C and Maccio A. Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. Drug Des Devel Ther. 2013; 7:645-656.
7. Ding GX, Feng CC, Song NH, Fang ZJ, Xia GW, Jiang HW, Hua LX and Ding Q. Paraneoplastic symptoms: Cachexia, polycythemia, and hypercalcemia are, respectively, related to vascular endothelial growth factor (VEGF) expression in renal clear cell carcinoma. Urol Oncol. 2012.
8. Oya M. Renal cell carcinoma: biological features and rationale for molecular-targeted therapy. Keio J Med. 2009; 58(1):1-11.
9. van der Veldt AA, Haanen JB, van den Eertwegh AJ and Boven E. Targeted therapy for renal cell cancer: current perspectives. Discov Med. 2010; 10(54):394-405.
10. Motzer RJ, Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST, et al. Sunitinib in patients with metastatic renal cell carcinoma. JAMA. 2006; 295(21):2516-2524.
11. Escudier B and Kataja V. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010; 21 Suppl 5:v137-139.
12. Singer EA, Gupta GN and Srinivasan R. Targeted therapeutic strategies for the management of renal cell carcinoma. Curr Opin Oncol. 2012; 24(3):284-290.
13. Argiles JM, Busquets S, Stemmler B and Lopez-Soriano FJ. Cancer cachexia: understanding the molecular basis. Nat Rev Cancer. 2014; 14(11):754-762.
14. Penna F, Costamagna D, Fanzani A, Bonelli G, Baccino FM and Costelli P. Muscle wasting and impaired myogenesis in tumor bearing mice are prevented by ERK inhibition. PLoS One. 2010; 5(10):e13604.
15. Bodine SC, Latres E, Baumhueter S, Lai VK, Nunez L, Clarke BA, Poueymirou WT, Panaro FJ, Na E, Dharmarajan K, Pan ZQ, Valenzuela DM, DeChiara TM, et al. Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547):1704-1708.
16. Gomes MD, Lecker SH, Jagoe RT, Navon A and Goldberg AL. Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001; 98(25):14440-14445.
17. Bonetto A, Aydogdu T, Jin X, Zhang Z, Zhan R, Puzis L, Koniaris LG and Zimmers TA. JAK/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia. Am J Physiol Endocrinol Metab. 2012; 303(3):E410-421.
18. Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007; 356(2):125-134.
19. Aulino P, Berardi E, Cardillo VM, Rizzuto E, Perniconi B, Ramina C, Padula F, Spugnini EP, Baldi A, Faiola F, Adamo S and Coletti D. Molecular, cellular and physiological characterization of the cancer cachexia-inducing C26 colon carcinoma in mouse. BMC Cancer. 2010; 10:363.
20. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 2007; 356(22):2271-2281.
21. Wang XH and Mitch WE. Muscle wasting from kidney failure-a model for catabolic conditions. Int J Biochem Cell Biol. 2013; 45(10):2230-2238.
22. Acharyya S, Ladner KJ, Nelsen LL, Damrauer J, Reiser PJ, Swoap S and Guttridge DC. Cancer cachexia is regulated by selective targeting of skeletal muscle gene products. J Clin Invest. 2004; 114(3):370-378.
23. Cohen S, Brault JJ, Gygi SP, Glass DJ, Valenzuela DM, Gartner C, Latres E and Goldberg AL. During muscle atrophy, thick, but not thin, filament components are degraded by MuRF1-dependent ubiquitylation. J Cell Biol. 2009; 185(6):1083-1095.
24. Lagirand-Cantaloube J, Cornille K, Csibi A, Batonnet-Pichon S, Leibovitch MP and Leibovitch SA. Inhibition of atrogin-1/MAFbx mediated MyoD proteolysis prevents skeletal muscle atrophy in vivo. PLoS One. 2009; 4(3):e4973.
25. Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH and Goldberg AL. Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 2004; 117(3):399-412.
26. Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD and Glass DJ. The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors. Mol Cell. 2004; 14(3):395-403.
27. Argiles JM, Busquets S, Toledo M and Lopez-Soriano FJ. The role of cytokines in cancer cachexia. Curr Opin Support Palliat Care. 2009; 3(4):263-268.
28. Bonetto A, Aydogdu T, Kunzevitzky N, Guttridge DC, Khuri S, Koniaris LG and Zimmers TA. STAT3 activation in skeletal muscle links muscle wasting and the acute phase response in cancer cachexia. PLoS One. 2011; 6(7):e22538.
29. Zhang L, Pan J, Dong Y, Tweardy DJ, Garibotto G and Mitch WE. Stat3 activation links a C/EBPdelta to myostatin pathway to stimulate loss of muscle mass. Cell Metab. 2013; 18(3):368-379.
30. Tierney MT, Aydogdu T, Sala D, Malecova B, Gatto S, Puri PL, Latella L and Sacco A. STAT3 signaling controls satellite cell expansion and skeletal muscle repair. Nat Med. 2014; 20(10):1182-1186.
31. Tsoli M, Schweiger M, Vanniasinghe AS, Painter A, Zechner R, Clarke S and Robertson G. Depletion of white adipose tissue in cancer cachexia syndrome is associated with inflammatory signaling and disrupted circadian regulation. PLoS One. 2014; 9(3):e92966.
32. Zhou X, Wang JL, Lu J, Song Y, Kwak KS, Jiao Q, Rosenfeld R, Chen Q, Boone T, Simonet WS, Lacey DL, Goldberg AL and Han HQ. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010; 142(4):531-543.
33. Baumgarten AJ, Fiebig HH and Burger AM. Molecular analysis of xenograft models of human cancer cachexia--possibilities for therapeutic intervention. Cancer Genomics Proteomics. 2007; 4(3):223-231.
34. Xue Y, Religa P, Cao R, Hansen AJ, Lucchini F, Jones B, Wu Y, Zhu Z, Pytowski B, Liang Y, Zhong W, Vezzoni P, Rozell B, et al. Anti-VEGF agents confer survival advantages to tumor-bearing mice by improving cancer-associated systemic syndrome. Proc Natl Acad Sci U S A. 2008; 105(47):18513-18518.
35. Wong AK, Alfert M, Castrillon DH, Shen Q, Holash J, Yancopoulos GD and Chin L. Excessive tumor-elaborated VEGF and its neutralization define a lethal paraneoplastic syndrome. Proc Natl Acad Sci U S A. 2001; 98(13):7481-7486.
36. Wang X, Crowe PJ, Goldstein D and Yang JL. STAT3 inhibition, a novel approach to enhancing targeted therapy in human cancers (review). Int J Oncol. 2012; 41(4):1181-1191.
37. Gilabert M, Calvo E, Airoldi A, Hamidi T, Moutardier V, Turrini O and Iovanna J. Pancreatic cancer-induced cachexia is Jak2-dependent in mice. J Cell Physiol. 2014; 229(10):1437-1443.
38. Naito S, von Eschenbach AC, Giavazzi R and Fidler IJ. Growth and metastasis of tumor cells isolated from a human renal cell carcinoma implanted into different organs of nude mice. Cancer Res. 1986; 46(8):4109-4115.
39. Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, Double JA, Everitt J, Farningham DA, Glennie MJ, Kelland LR, Robinson V, Stratford IJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010; 102(11):1555-1577.
40. Luu YK, Lublinsky S, Ozcivici E, Capilla E, Pessin JE, Rubin CT and Judex S. In vivo quantification of subcutaneous and visceral adiposity by micro-computed tomography in a small animal model. Med Eng Phys. 2009; 31(1):34-41.